{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T10:34:40Z","timestamp":1717756480876},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.lungcan.2015.08.020","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T11:30:37Z","timestamp":1441366237000},"page":"261-266","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs"],"prefix":"10.1016","volume":"90","author":[{"given":"Su Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.lungcan.2015.08.020_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.10-90003-1","article-title":"Optimizing first-line treatment options for patients with advanced NSCLC","volume":"10","author":"Wakelee","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2015.08.020_bib0010","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0020","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0035","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0045","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-Small Cell Lung Cancer [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2015 [cited 2015 May 20]. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ijc.24657","article-title":"Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer","volume":"126","author":"Wu","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2015.08.020_bib0055","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0060","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2015.08.020_bib0070","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0075","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0080","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2015.08.020_bib0085","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0090","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/annonc\/mdm564","article-title":"Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19\/03","volume":"19","author":"D'Addario","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0095","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial","volume":"30","author":"Gridelli","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/OTT.S62639","article-title":"tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma","volume":"7","author":"Tseng","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0105","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2014.244","article-title":"Pemetrexed Singlet versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-Small Cell Lung Cancer Patients with EGFR Mutations","author":"Park","year":"2015","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0110","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0115","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1002\/cncr.27630","article-title":"Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial","volume":"118","author":"Sun","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2015.08.020_bib0120","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu438.50","article-title":"Cisplatin plus pemetrexed (CP) versus cisplatin plus gemcitabine (CG) according to thymidylate synthase expression in non-squamous NSCLC: a biomarker-stratified randomized phase II trial","volume":"25","author":"Ahn","year":"2014","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2015.08.020_bib0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500215300441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T18:51:30Z","timestamp":1537383090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500215300441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0169500215300441"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.08.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}